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The Royal Society convened a meeting on the 17th and 18th November 2010 to review the current
ways in which vaccines are developed and deployed, and to make recommendations as to howeach of
these processes might be accelerated. The meeting brought together academics, industry representa-
tives, research sponsors, regulators, government advisors and representatives of international public
healthagenciesfromabroadgeographicalbackground.DiscussionswereheldunderChathamHouse
rules. High-throughput screening of new vaccine antigens and candidates was seen as a driving force
for vaccine discovery. Multi-stakeholder, small-scale manufacturing facilities capable of rapid pro-
duction of clinical grade vaccines are currently too few and need to be expanded. In both the
human and veterinary areas, there is a need for tiered regulatory standards, differentially tailored
for experimental and commercial vaccines, to allow accelerated vaccine efﬁcacy testing. Improved
cross-fertilization of knowledge between industry and academia, and between human and veterinary
vaccine developers,could lead tomorerapidapplicationofpromisingapproachesandtechnologiesto
new product development. Identiﬁcation of best-practices and development of checklists for product
development plans and implementation programmes were seen as low-cost opportunities to shorten
the timeline for vaccine progression from the laboratory bench to the people who need it.
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1. INTRODUCTION
Vaccinesarethegreatestcontributionmodernmedicine
has made to humanity, providing a powerful and cost-
effective intervention to prevent deadly diseases.
Successfulimmunizationcampaignshaveachievederadi-
cation of smallpox and rinderpest (a viral disease of
cattle) and poliomyelitis is close to worldwide elimin-
ation. In spite of these strides, infectious diseases still
kill millions of people every year, with developing
countries remaining particularly vulnerable. The devel-
opment of a human vaccine from concept to licensure
currently takes at least 15 years, while introduction
plans for global deployment extend in most cases
beyond 20 years, with coverage reaching no more than
80 per cent of the target population even in the best-
case scenarios. These protracted timelines for much
neededinterventionsagainstendemicinfectiousdiseases
come at a huge human cost and demand serious atten-
tion. Furthermore, the recent severe acute respiratory
syndrome(SARS)outbreak,thecontinuingriskofapan-
demic of severe avian inﬂuenza and the recent H1N1
pandemic have reinforced the need for a rapid global
response to pandemics. For these reasons, the inter-
national community needs to be able to develop and
deploy new vaccines more rapidly than has been the
caseinthepast.Inaimingtoidentifyablueprintforaccel-
erated vaccine development, experts considered the
current status of vaccine platforms in various parts of
the world, reviewed some of the constraints to more
rapid development and deployment of vaccines, and
ﬁnally considered how some of these constraints might
be addressed.
2. CURRENT TRENDS IN VACCINE
DEVELOPMENT
While the world is affected today by a greater number
of infectious diseases than ever before, many of which
are zoonoses and mainly prevalent in poor countries,
their infrequent occurrence in rich countries has led
to a decline in investment, research infrastructure
and expertise dedicated to infectious diseases in
afﬂuent, industrialized nations. Different perceptions
of threat and public health priorities can thus be
observed in three groups of countries: industrialized
countries, innovative emerging economies and high-
burden resource-poor settings. The attendees grappled
with the relevance of these trends to the future of
vaccine development.
* Author for correspondence (migena.bregu@ndm.ox.ac.uk).
One contribution of 16 to a Discussion Meeting Issue ‘New vaccines
for global health’.
Phil. Trans. R. Soc. B (2011) 366, 2841–2849
doi:10.1098/rstb.2011.0100
2841 This journal is q 2011 The Royal Society(a) Trends in industrialized countries
Although deaths from infectious disease still occur
in wealthy countries, particularly in marginalized
populations,improvedpublichealthmeasureshave suc-
ceeded in reducing the toll from infectious diseases and,
as a consequence, governments in rich nations are
investinglessininfectiousdiseasescontrolandresearch.
Investments in vaccine development have been very
different for infectious diseases that affect both rich
and poor countries, for example, human immunodeﬁ-
ciency virus (HIV) and human papillomavirus (HPV),
compared with neglected tropical diseases (NTDs),
which are exclusively endemic in low-income countries.
Pharmaceutical companies are primarily focused on
developing interventions for infectious diseases that
affect industrialized nations, while investment in vac-
cines for NTDs has come largely from philanthropy,
with most research and development (R&D) being
undertaken by academic teams in alliance with a few
product development partnerships (PDPs). While a
huge investment in interventions for NTDs has already
been made by charitable organizations such as the Bill
and Melinda Gates Foundation, fear of lack of funding
is reducing the size of the infectious diseases research
communityinsomedevelopedcountriesandweakening
capacity for the exploratory and discovery activities that
are key to identifying new interventions.
Signiﬁcant anti-vaccination campaigns have taken
root in many industrialized nations in spite of scientiﬁc
ﬁndings refuting many unsubstantiated fears about
vaccination. Attendees expressed concern that anti-
vaccination bias in developed nations is not only
having a serious negative impact on health campaigns
in developing countries, but is also affecting the regula-
toryframeworkofthedevelopedworld,wherethefearof
litigation is compromising a balanced risk–beneﬁt
assessment of much needed interventions. As vaccine
safety requirements become more demanding, the cost
of vaccine development and exhaustive safety testing
are dampening the incentive of the pharmaceutical
industry to develop vaccines for diseases of populations
with limited purchasing power.
(b) Trends in innovative developing countries
In the past two decades, there has been an import-
ant change in the global economic and scientiﬁc
landscape. The economies of China, India, South
America, South Africa, Eastern Europe and the
Middle East have risen in economic standing and
many are investing substantially in state-of-the-art bio-
medical research infrastructures. These countries are
placing substantial emphasis on the build-up of local
scientiﬁcandtechnicalexpertiseandareputtingincreas-
ing resourcesintonurturing indigenousscientiﬁctalent.
Pharmaceutical companies are increasingly seeking to
manufacture vaccines in countries where the vaccines
are to be marketed, leading to a number of productive
partnerships between large multi-national companies
like GlaxoSmithKline (GSK), Pﬁzer, Sanoﬁ Pasteur
and innovative developing country (IDC) governments.
Asaresult,thenumberofproductionunitsformanufac-
turing drugs and vaccines and international research
institutes operating effectively in IDC has expanded.
The Developing Country Vaccine Manufacturers’
Network (www.dcvmn.com), established in 2005, is
increasingly engaged with supplying vaccines at afford-
able prices through UNICEF tenders to meet the
health needs of the poor.
(c) Trends in resource-poor developing countries
Sub-Saharan Africa continues to be the greatest con-
cern as the prevalence of infectious diseases remains
high and ability to pay for new health interventions
remains low. In contrast to IDC countries, technology
transfer to sub-Saharan Africa, with the exception of
South Africa, remains low and there is little to no
capital support for vaccine R&D. A lack of investment
in vaccine and drug manufacturing is resulting in the
dismantling of the few pre-existing manufacturing
centres—a striking example being the loss of manufac-
turing capability that was set up in Nigeria for yellow
fever vaccine. Given the positive examples of IDC
countries, there is a major need to create and support
regional centres of scientiﬁc and technical excellence
in Africa. Programmes that support training of African
scientists in partnership with international scientiﬁc
centres and industry need to be encouraged through
new and innovative means. Development agencies
should be encouraged to invest in Africa to build
capacity in infrastructure, with private and public
investors as complementary pillars to that of inter-
national aid, and with African business players taking
the lead in supporting technological advances that
will serve the needs of their continent.
Attendees stressed that public health measures,
including a number of successful vaccination pro-
grammes, have been greatly beneﬁcial to both rich
countries and the developing world; for example, vac-
cines against Haemophilus inﬂuenzae type b (Hib),
pneumococcal and rotavirus infections. However, com-
placency, which dilutes the infrastructure for vaccine
development, is very risky, especially at a time when
increased international travel, evolution of drug resist-
ance, climate change and the threat of bioterrorism
make the age-old battle of humans against infectious
disease more challenging. The re-emergence of killer
diseases such as drug-resistant tuberculosis (MDR-
TB) in Western Europe provides a warning that wealthy
nations are not immune to the diseases of the poor. A
versatile knowledge base and more frequent ﬂow of
information and technology transfer between industry
and academia, and between disease endemic regions
and knowledge-based economies, are essential, if
public health measures are to fulﬁl their potential to
improve the lives of populations globally.
Focusingonvaccine-basedinterventions,theexpertsset
outtoidentifyforcesthatwouldenablevaccinedevelop-
ment to meet the demands of the twenty-ﬁrst century.
Three main agendas were reviewed: (i) achieving faster
vaccine discovery and development; (ii) expediting
the path of vaccine implementation in target popu-
lations; and (iii) securing increased ﬁnancial aid for
immunization programmes, supplemented with better
advocacy to ensure strong public support for their
implementation.
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PRIORITIES
(a) Accelerating experimental vaccinology
(i) Rapid testing of new platforms
The development of a successful human vaccine, from
idea to licensure, is a complex process (ﬁgures 1 and 2)
and is estimated to take over 15 years—a timeline
judged by most to be too long. Most infectious diseases
for which vaccines are needed urgently are far from
being ‘easy targets’ and thus accelerated early-phase
testing of vaccine candidates developed using a variety
ofdifferentapproachesisnecessarytoidentifyefﬁcacious
candidates. In the exploratory phase, more rapid
and high-throughput testing of new vaccine antigens
and delivery platforms is essential to establish early
proof-of-concept. Usually, interest in these endeavours
is driven by academic groups, but currently most
lack access to the long-term investment in infrastructure
required to undertake translational studies into humans.
Conversely, industry requires a high-level of conﬁ-
dence in technologies and formulations required for
product development if it is to permit early ‘at-risk’
investment. Lack of knowledge regarding protective
immune responses, and/or how these can be induced in
humans, condemn many difﬁcult and scientiﬁcally neg-
lected infectious diseases to the ‘too high risk’ bracket.
Industry generally prefers tried and tested delivery plat-
forms for new vaccines as these can be more easily
aligned with established manufacturing capabilities and
a commercial target product proﬁle (TPP). This align-
ment leaves little to no room for innovative but
unvalidated vaccine delivery technologies, such as for-
mulations with improved thermal stability or needle-
free administration, to enter the product development
path. How then can the accelerated testing of new tech-
nologies be integrated with new product development?
Two main approaches were proposed. Veterinary vac-
cines could lead the way in validating the performance
of new technologies, establishing the amenability of the
technology to manufacturing scale-up and to meeting
regulatory standards. This would be supported by the
lower cost of obtaining efﬁcacy data, usually with
microbial challenge studies, in host animal species. The
validation and regulatory approval of novel technologies
for veterinary interventions could reduce the risk of
embedding the new technologies and manufacturing
platforms into the development of human vaccines.
Alternatively, human vaccine developers could be more
proactive in testing innovative formulations and deliver-
ing technologies during the development of improved
second-generation products. The introduction of new
technologies insuchamannercouldleadintoinnovative
delivery and formulation approaches reaching routine
immunizations over the course of time, and overcome
thecurrentsituationwheresomeinnovativetechnologies
lapse because they are not taken up by the industry.
(ii) Infrastructure to support small-scale, high-throughput,
vaccine manufacturing and clinical testing
The attendees suggested that new innovative ways
of developing infrastructure to support small-scale,
proof-of-concept vaccine development are of high
priority. Similarly, manufacturing standards and
production volumes should be tailored to assist early-
phase vaccine development, making these endeavours
more affordable and, most importantly, more high-
throughput. The cost of good manufacturing practice
(GMP) and associated quality control and quality
assurance of experimental vaccines can be prohibi-
tively high for academic groups and often similar
standards are applied to small-scale manufacturing
batches and manufacturing for market supply. The
underlying high costs of GMP prevent important com-
parative testing of vaccine candidates in early-phase,
proof-of-concept human clinical trials. An academic
centre is fortunate if it secures sufﬁcient funding to
take even a single candidate vaccine through GMP
manufacture and into a phase I clinical trial. It was
stressed that suitable modiﬁcations of GMP standards
could be identiﬁed that would not compromise safety,
but could facilitate comparative testing of experimental
vaccines. The use of single-product GMP production
suites, or GMP labelling systems for experimental
vaccines which are equivalent to labelling requirements
for commercial vaccines were highlighted as two
examples of requirements that could be adjusted for
experimental vaccines to facilitate lower cost pilot
GMP lot production. Utilization of new and more
efﬁcient vaccine production platforms, such as modular
bioreactors and mobile clean rooms, could also help to
meet this need in the future.
It was highlighted that in the ﬁeld of veterinary medi-
cine, the need is for ‘effective’ vaccines rather than
‘perfect’vaccines.Veterinaryvaccineregulatoryrequire-
ments could be less stringent than for human vaccines
and new GMP facilities could gain crucial experience
in the manufacture of animal vaccines prior to proceed-
ing with the more stringent production of human
products. This approach could lead to the accelerated
deployment of new innovative technologies and the
establishment of new GMP facilities. This principle is
already gaining some acceptance as multiple vaccines
based on the new DNA-based vectors are now licensed
for veterinary use, including 12 recombinant viral-vec-
tored vaccines as well as four DNA plasmid vaccines
(table 1). In contrast, in the human ﬁeld, the ﬁrst vec-
tored vaccine, a chimeric ﬂavivirus against Japanese
encephalitis, is only just reaching regulatory approval.
In order to facilitate vaccine discovery, the develop-
ment of more academic vaccine centres should be
encouraged, which allow for vaccine development to
take place in fruitful, multi-disciplinary environments.
Funders of academic groups working on translational
research need to appreciate that the timelines for vaccine
development will exceed those of traditional research
grants in order to provide continued incentive for aca-
demics to work in this area. Calls were made for funders
to invest in new technologies as well as in the next gener-
ation of scientists who will pursue careers in vaccine
development and who will be able to apply recent
advances in immune proﬁling and systems biology to the
development of innovative new vaccines against the most
elusive diseases.
(iii) Multi-stakeholder support for the infrastructure needed
for vaccine development
Vaccine development requires the input of a hugely
diverse skill set, and it was suggested that a much
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research preclinical Phl Phll Phlll/IV
R, D & C
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selected
Tox and CTM
completed
dose, interval,
+/– adjuvant ‘efficacy’
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￿ Phlll CTM production
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￿ clinical assays established
￿ antigen delivery platforms
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￿ formulation and analytical
￿ pre-IND meeting
￿ formulation identified
Figure 2. Accelerating the vaccine product development pathway. Ways in which candidate vaccines could be advanced to
licensure within 8–10 years, if all players in the process are aligned from the outset. IND, investigational new drug application;
CTM, clinical trial manufacturing. (Contribution of James Merson, Pﬁzer.)
Table 1. DNA and viral-vectored veterinary vaccines licensed for commercial use (adapted from Draper, S. J. & Heeney,
J. L. 2010 Nat. Rev. Microbiol. 8, 62–73).
recombinant vector vaccine target/indication
target
species target antigen(s) brand name distributor
DNA West Nile virus horse pre-membrane and
envelope (preM-Env)
West Nile-Innovator Fort Dodge
Animal
Health
DNA melanoma dogs human tyrosinase Oncept Merial
DNA infectious haematopoietic
necrosis virus
salmon glycoprotein Apex-IHN Novartis
Animal
Health
DNA increase litter survival swine growth hormone
releasing hormone
Life Tide SW5 VGX Animal
Health,
Inc.
attenuated
Canarypox
(ALVAC)
West Nile virus horses preM-Env Recombitek Equine
WNV
Merial
ALVAC (plus
Tetanus Toxoid
and Carbopol
Adjuvant)
equine inﬂuenza virus horses haemagglutinin (HA)
(Kentucky and
Newmarket strains)
ProteqFlu-Te
(Europe)
Recombitek (USA)
Merial
ALVAC rabies cats glycoprotein G (gG) Purevax Feline
Rabies
Merial
ALVAC feline leukaemia virus cats Env, Gag/Pol Purevax FeLV Merial
ALVAC canine distemper virus dogs HA and fusion antigen
(F)
RECOMBITEK
rDistemper
Merial
ALVAC canine distemper virus ferrets HA and F Purevax Ferret
Distemper
Merial
Fowlpox virus
(FPV)
avian inﬂuenza virus and
FPV
poultry H5 HA Trovac AI H5 Merial
FPV Newcastle disease virus
(NDV) and FPV
poultry haemagglutinin-
neuraminidase (HN)
and F
Vectormune FP-N Biomune
Vaccinia rabies virus wildlife gG Raboral Merial
Newcastle disease
virus (LaSota
strain)
avian inﬂuenza virus and
NDV
poultry H5 HA NewH5 Avimex
Flavivirus YFV-17D
(live chimeric
virus)
West Nile virus horses preM-Env of WNV in
yellow fever virus
(YFV)-17D
backbone
PreveNile Intervet
Turkey herpesvirus
(HVT) (live
chimeric virus)
infectious bursal disease
virus (IBDV) and
Marek’s disease virus
(MDV)
poultry viral protein 2 (VP2) of
IBDV in HVT
backbone
Vaxxitek HVT þ IBD Merial
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ing approach could help to accelerate early-phase
vaccine development. Pharmaceutical companies have
invested heavily in recent years to provide infrastructure
that can cater for twenty-ﬁrst century needs relating to
antimicrobials, therapeutics, vaccines and diagnostics.
In developed countries, designated facilities have also
been established through public funds to address the
needs ofbiodefence andthe threatfromnewlyemerging
infectious and zoonotic diseases. It was suggested that
similar multi-stakeholder, publicly funded, GMP facili-
ties could be established to provide a cost-effective
means to develop multiple, experimental vaccine candi-
dates. These could potentially cater for a wide range of
new generation vaccine delivery technologies and,
importantly,couldprovidecapacityfor veryrapidemer-
gency vaccine manufacture in response to disease
outbreaks—a so-called model of ‘PERManEnt facility’
(Pandemic Emergency Response Manufacturing Enter-
prise) was proposed. This type of facility would aim to
shorten the current timelines for new vaccine develop-
ment in the event of a new SARS-like outbreak from
months to weeks. However, it was noted that issues of
liability could deter the participation of industry in
such multi-stakeholder GMP ventures.
(iv) Access to vaccine adjuvants—a global ‘crisis’?
The global‘crisis’regarding accessto promising vaccine
adjuvants was discussed. A signiﬁcant difﬁculty for vac-
cine research in academia has been the lack of access to
manyofthepromisingadjuvants,developedbycompan-
ies that have been unwilling to share these with external
investigators. Greater ease of access to such adjuvants
could signiﬁcantly accelerate experimental vaccinology
and expedite identiﬁcation of preferred adjuvants for
particular vaccines. Lack of access has prevented com-
parative testing of many adjuvant formulations both in
pre-clinical and clinical studies, and has had a particu-
larly adverse effect on vaccine development for
diseases for which there is limited commercial interest
and for which very strong immune responses are
required for protection. In an attempt to remedy this
problem, some non-proﬁt organizations, with support
from major funding agencies, have established a new
Global Adjuvant Development Initiative (GADI)
laboratory under the guidance of the World Health
Organization (WHO), located at the University of
Lausanne. GADI is supporting mechanisms to make
adjuvants available to public-sector vaccine developers.
It was stressed by delegates from industry that liability
issues can prohibit the sharing of adjuvants used for
commercial vaccines, but that some adjuvants which
are in the R&D pipeline could be shared with
academic and public-sector partners.
(b) Accelerating the product development path
While doubts were expressed as to whether it is possible
toexpediteearly-phasecandidatevaccinetestingfordif-
ﬁcult diseases, it was agreed that there is more scope for
progress with regard to accelerated product develop-
ment pathways. Early alignment of key players in the
process is essential, and this can help to establish a
clear line of sight from product development to vaccine
registration. Strides should be made to establish the
TPP, essentially deﬁning the ‘label on the vial’ from
the outset, start pilot process development at the same
time asR&Dandinstigatea process ofsmall,rapid,par-
allel clinical trials to ascertain safety and efﬁcacy in the
target population, ideally also identifying a bioassay of
vaccine efﬁcacy. In order to expedite vaccine licensure,
clinical testing should consist of ‘rolling’ phase I/II
trials leading into a phase III trial in the minimum
number of countries with all bioassays performed in a
single reference laboratory. The clinical testing of
Prevnar-13 in The Netherlands was highlighted as a
best-practice example. If all these processes are aligned,
candidate vaccines can be advanced to registration in
8–10years (ﬁgure 2). It was noted that acceleration of
the pathways that lead to product licensure will most
probably require a larger set of post-licensure studies
(e.g. of performance in special populations, extended
safety, impact on other immunizations); however, this
was viewed as a favourable strategy in the context of
beneﬁts arising from accelerated vaccine deployment.
4. IMPLEMENTATION PRIORITIES
(a) The science of implementation: identifying
best-practice for taking vaccines from licensure
to deployment
Once licensed, vaccines still face an uphill struggle to
ensure wide-scale deployment in the communities
where the vaccines have the greatest potential to make
an impact. It seems likely that the deployment of pneu-
mococcal conjugate vaccines in developing countries
will be faster than that achieved for the Hib conjugate
vaccine, in part as a result of lessons learnt during the
course of the activities of the Hib initiatives and those
of the pneumococcal accelerated development and
introduction of priority new vaccines plan (ADIP;
ﬁgure 3). These two immunization programmes pro-
vide a striking example of how much could be gained
by improving the process of vaccine implementation.
The ‘science of vaccine implementation’ still remains
in its infancy, although there are success stories at
national level such as the introduction of the HPV vac-
cine for teenage girls in the UK in 2008/2009 with
greater than 80 per cent coverage achieved in the ﬁrst
year. Positive examples and best practice at national
and international levels could be used to design a guid-
ing framework for vaccine deployment with maximal
coverage and minimal time lag between licensure and
widespread deployment.
Better understanding of the data required to guide
vaccine implementation and the development of
‘checklists’ to guide decision-making at various levels
in the implementation of vaccination programmes
were considered of paramount importance for efﬁcient
vaccine introduction. Dedicated teams are required to
work on the development of these processes and
guidelines. As part of the implementation prepared-
ness, disease endemic countries need to establish a
strong ‘pull’ factor that ensures demand for a vac-
cine. This requires governments of these countries to
understand the burden of disease, be engaged in
implementation plans, contribute to vaccine pro-
curement and advocate their use. This process will
require long-term collaborations to be established
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5. REGULATORY REFORM
Regulatory reforms were viewed as important ways to
achieve faster clinical testing and licensure of new,
innovative vaccines. Discussion focused on whether a
universal regulatory framework or a case-speciﬁc
assessment of risks and beneﬁts linked to each medical
product would be better placed to support health
interventions in the twenty-ﬁrst century. It was noted
that maintaining consistent global standards with
regard to risk–beneﬁt analysis is essential. However, it
was stressed that no universal interpretation of such
an analysis can apply as disease epidemiology, morbid-
ity and mortality vary so widely with geographical
location.
The development of a methodological framework
based on consistent and universally acceptable stand-
ards of risk–beneﬁt analysis would support a
regulatory assessment that takes into consideration
how a speciﬁc preventive intervention impacts on the
disease and health pattern in a particular region. A
legal framework that offers ﬂexibility for a case-by-
case assessment on a beneﬁt–risk basis, with rigor-
ously maintained standards, was seen as the best way
to maintain the timely and rapid licensure of new vac-
cines. It was agreed that weak, inﬂexible regulation
would hinder, rather than accelerate, the progression
of much needed vaccines to market, as well as risk
undermining public and industrial conﬁdence in the
regulatory system. The need to structure regulatory
standards in tiers for human versus veterinary vaccines
and experimental versus commercial applications was
identiﬁed as a timely reform that would transform
the regulatory landscape (ﬁgure 1).
In the case of veterinary vaccines, comparisons were
drawn between developing countries, where the regu-
latory infrastructure remains weak, and developed
countries, where regulation is strong and detailed.
Examples were cited from the European Union,
where manufacturing standards can be considered as
unnecessarily high for some veterinary vaccines,
making the production of these vaccines fairly expens-
ive. Many European farmers are unwilling to pay such
high prices, leading to potential loss of vaccine
demand or market ‘pull’ factors. This was contrasted
to developing countries where, for example, the
Maasai in East Africa are willing to pay relatively
high prices for cattle vaccines (up to US$4), owing
to their understanding that healthy livestock are a
pathway out of poverty. Striking the right regulatory
balance in the veterinary ﬁeld will be essential to the
future deployment and widespread use of accessible
and affordable veterinary vaccines to the millions in
developing countries for whom livestock are a lifeline.
6. INCREASED FINANCIAL AND PUBLIC
SUPPORT FOR IMMUNIZATION PROGRAMMES
(a) Innovative partnerships and ﬁnancing
Given the need to combat highly complex infectious
diseases and the unequal distribution of resources to
meet these challenges across geographical locations,
support for initiatives that increase the diversity of
technical, organizational and institutional arrange-
ments in which multi-disciplinary scientiﬁc research
is conducted was considered of paramount import-
ance. Identiﬁcation of positive examples and
dissemination of knowledge about the value obtained
from successful industry–academia–public-sector
partnerships can help in the design of new collective
institutions or partnerships. The attendees empha-
sized that policymakers and funders need to ﬁnd
new ways to create the conditions needed for entrepre-
neurial, multilateral enterprises and then to initiate
and fund them. In Europe, the Wellcome Trust has
expanded its funding portfolio to include joint ven-
tures between industry, academic groups and PDPs.
The establishment of the MSD-Wellcome Trust Hille-
man Laboratories in India in 2009 is a prime example
of a research charity and a pharmaceutical company
engaging in a joint venture with equally shared funding
and decision-making rights to establish a research
centre with a focus on developing vaccines for diseases
of poverty. This partnership combines the ingenuity of
academicresearchwiththeknow-howofindustry,aiming
tointegratethebestofbothinsettinguparesearchcentre
that operates like a business with product-focused goals,
but with a not-for-proﬁt ﬁnancial model. This is a an
ongoing experiment which, if successful, may encourage
otherstofollowthisdirectionandhelptoaddressthecriti-
calgapthatresultsinpromisingexperimentalapproaches
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Figure 3. Accelerating vaccine delivery. Comparison of the timeline for the processes involved in the implementation of pneu-
mococcal vaccine versus the implementation of Hib vaccine. ADIP, accelerated development and introduction plan.
(Contribution of Orin Levine, Johns Hopkins Bloomberg School of Public Health.)
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of low proﬁtability. Another model of multiparty collab-
orative networks is the TRANSVAC infrastructure
project (www.transvac.org), funded under the European
Commission’s 7th Framework Programme and coordin-
ated by the European Vaccine Initiative (EVI), set up
to create a cluster of knowledge and research infrastruc-
ture for the respective beneﬁt of collaborative partners
to have access to adjuvants, animal models, standardized
reagents and assays, as well as microarray analysis. The
experts recognized that there is a need for various stake-
holders to commit knowledge, expertise and funds to
ensure that these initiatives prosper.
(b) Improved priority setting and advocacy
Establishing ‘end-user priorities’ was seen as one of the
most critical issues needed to ensure that the vaccine
development pipeline meets true needs in the ﬁeld,
and this prioritization strategywasseen as an important
component of the best-practice implementation pro-
gramme. There was a consensus that communication
and engagement with governments and healthcare
workers in disease endemic regions should start as
early as possible in vaccine development programmes.
A multi-level model of stakeholder engagement needs
to be developed, which takes into account the different
needs of various target groups as well as any epidemio-
logical changes that may take place during the 10–15
years of vaccine development. To better understand
the needs of the end-users, emphasis was put on
community engagement and the use of culturally
appropriate informed consent for clinical studies. The
demand for Halal certiﬁcation to gain consumer conﬁ-
dence in the Middle East was used as an example to
highlight the importance of an early appreciation of
end-user expectations.
Improved understanding between governments of
disease endemic regions, the WHO, the Global Alliance
for Vaccines and Immunization (GAVI) and industry
was considered essential to guide implementation
decisions for new vaccines. The possibility of allowing
countries to lodge applications for vaccines before
pre-qualiﬁcation was proposed as a means to accelerate
vaccine availability. It was also emphasized that GAVI
needs to engage with governments of developing
countries to ensure that their national health budgets
have provisions to support vaccination after GAVI sub-
sidies end. This will help to establish a long-term ‘pull’
mechanism for new interventions in endemic regions.
Similarly, the importance of establishing the driving
forces within the commercial market was also stressed.
The role of farmers and pet owners as primary custo-
mers for veterinary vaccines was contrasted to human
vaccines, whereby purchasing occurs at the level of
national health systems and where advocacy and polit-
ical will for targeting a speciﬁc public health need to
underpin the ‘pull’ factor for a speciﬁc intervention.
Endeavours to develop life-saving vaccines must be
matched by clear and accessible information about the
value of vaccination. Governments and private funders
must be provided with evidence-based information
about the need for investment in vaccine development
and support for immunization programmes, while the
public must be provided with clear and accessible
information about the value of vaccination as a
public health intervention. A greater role was seen
for national academies of sciences and learned
societies in promoting scientiﬁc-based support for
vaccination programmes.
For communication strategies to have an impact,
opinions and recommendations need to come from
experts who are independent of proﬁt-making interest
groups and of government inﬂuence. One proposal
was put forward to set up independent vaccine infor-
mation institutes as information dissemination centres
committed to the improvement of public knowledge
about vaccines. No matter how strong the science may
be and how uniform the expert consensus, the general
publicwillremainsensitivetoalarmsraisedbyanti-vac-
cinationmovements,andwillbeswayedbytheopinions
of friends, actions of their peers and the media. This
needs to be accepted and responded to by teaming up
independent and informed advisors with parents’
groups, opinion leaders and media experts who can
address any real or unfounded fears and explain the
risks of vaccine apathy as well as vaccine use, adopting
the spectrum of modern communication channels to
which the younger generation is most amenable.
7. CONCLUSION
The meeting concluded with a review of the issues that
had been identiﬁed during the course of the discussion
as challenges to the accelerated development of new
vaccines (box 1), and with the identiﬁcation of some
of the ways in which these challenges could be met
(box 2).
Box 1. Challenges to the acceleration of vaccine
development and deployment.
— A growing number of academic centres are becom-
ing involved with experimental vaccinology.
However, funders of academic teams are not
aware of the protracted timelines and costs required
for vaccine discovery and clinical development.
— Fragmentation of immunological research into
domains of infectious disease and cancers of
humans and animals has thwarted the synergy that
could be obtained by undertaking a more combined
tactical approach.
— The costs of GMP and toxicology testing are
prohibitively high for new proof-of-concept vaccines
developed by academic groups.
— Uptake of new innovative vaccine delivery platforms
by industry remains low. Little technology and
knowledge transfer occur at the early stages of
vaccine development.
— Cross-fertilization of ideas and technologies
between industry and academia remains weak.
— The ‘science of vaccine implementation’ is under-
developed and long gaps between registration and
effective implementation are responsible for the
loss of many human lives.
— The TPP of a vaccine should be developed early
and tailored to the need(s) of the target population.
— The communication between different vaccine
stakeholders during the course of vaccine develop-
ment and implementation needs improving.
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are investing more in their health-based capabilities
both in terms of resources and expertise, but sub-
Saharan African countries are lagging behind.
— Regulatory frameworks are not ﬂexible enough to
facilitate accelerated testing and introduction of
innovative technologies.
— Financing remains an issue for NTDs. While there
is an increase in ﬁnancial support from philanthrop-
ic donors, public funding for vaccines against these
diseases has declined both in Europe and in the
USA.
— The inﬂuence of anti-vaccination lobbies threatens
to seriously undermine public conﬁdence in
immunization programmes and vaccines.
Box 2. Recommendations on how to tackle some of the
challenges that are impeding the development and
deployment of new vaccines.
— Best practices that could shorten the path of vaccine
development from 15–20 years to 10–15 years
need to be identiﬁed, validated and disseminated.
— The discovery phase for experimental vaccinology
should be strengthened by setting up publically sup-
ported, multi-stakeholder GMP and toxicology
facilities to support ‘experimental vaccines’. Intro-
duction of modular/self-contained manufacturing
bioreactors could enable faster throughput of vac-
cine candidates for proof-of-concept clinical trials.
— A more rational approach to vaccine design should
involve support for more multi-disciplinary investi-
gations of the immunological and systems
biological basis of disease and protective immunity.
— Veterinary vaccines and second-generation products
should lead the way for validating new and innova-
tive enabling technologies.
— Regulatory agencies should be more ﬂexible and
innovative in setting up a system of tiered regulatory
standards tailored to veterinary and human vac-
cines, which differentiates between experimental
and commercial applications.
— Regional capacity to support vaccine clinical testing
should be strengthened.
— A best-practice method for managing vaccine
implementation programmes to support a rapid
transition from vaccine licensure to national
immunization programmes should be developed.
— Improved communication and collaborations with
the governments of high-burden disease countries
are needed to ensure that the needs of end-users
are understood and met.
— National Academies of Sciences could help in pro-
ducing the information needed to counter the
efforts of the anti-vaccination lobbies.
— Establishing independent vaccine information
institutes, at the national level, to complement
WHO efforts and deliver online, accurate, publi-
cally accessible information related to vaccines
should be considered.
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